Learn more →
Back to Expert Scholars
melanoma / melanomaMelanoma Immunotherapy

Georgina Long

乔治娜·朗

MBBS, PhD

🏢Melanoma Institute Australia, University of Sydney(澳大利亚黑色素瘤研究所,悉尼大学)🌐Australia

Co-Medical Director, Professor of Melanoma Medical Oncology联合医疗主任,黑色素瘤肿瘤内科学教授

72
h-index
3
Key Papers
5
Awards
3
Key Contributions

👥Biography 个人简介

Georgina Long is co-medical director of Melanoma Institute Australia and a global leader in adjuvant and neoadjuvant immunotherapy for melanoma. Her landmark OpACIN and COMBI-AD trial contributions have transformed perioperative management and established Australia as a world center for melanoma research.

Share:

🧪Research Fields 研究领域

Melanoma黑色素瘤
Adjuvant Immunotherapy辅助免疫治疗
Neoadjuvant Therapy新辅助治疗
Combination Immunotherapy联合免疫治疗

🎓Key Contributions 主要贡献

Neoadjuvant Immunotherapy

Led OpACIN and OpACIN-neo trials establishing neoadjuvant ipilimumab-nivolumab as highly active in stage III melanoma, achieving major pathologic responses and reshaping surgical planning.

Adjuvant Targeted Therapy

Contributed to COMBI-AD trial demonstrating that adjuvant dabrafenib-trametinib significantly reduces relapse risk in resected BRAF-mutant stage III melanoma.

Multidisciplinary Melanoma Care

Developed and disseminated multidisciplinary care models integrating surgery, immunotherapy, and targeted therapy, improving outcomes and reducing mortality across Australian cancer centers.

Representative Works 代表性著作

[1]

Neoadjuvant Ipilimumab and Nivolumab versus Standard-of-Care in Melanoma (OpACIN-neo)

The Lancet Oncology (2019)

Defined optimal dosing of neoadjuvant dual checkpoint blockade achieving high pathologic complete response in stage III melanoma.

[2]

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma (COMBI-AD)

New England Journal of Medicine (2017)

Demonstrated 3-year relapse-free survival benefit of adjuvant BRAF/MEK inhibition, changing standard of care.

[3]

Five-Year Outcomes of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

New England Journal of Medicine (2022)

Confirmed durable long-term RFS and OS benefit of adjuvant targeted therapy in BRAF-mutant melanoma.

🏆Awards & Recognition 奖项与荣誉

🏆Australian of the Year NSW Finalist
🏆NHMRC Investigator Grant (Leadership Level)
🏆Cancer Institute NSW Premier's Award for Outstanding Cancer Research
🏆Melanoma Research Foundation Hero of Melanoma
🏆ESMO Award for Translational Research

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 乔治娜·朗 的研究动态

Follow Georgina Long's research updates

留下邮箱,当我们发布与 Georgina Long(Melanoma Institute Australia, University of Sydney)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment